DE60324250D1 - Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion - Google Patents

Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion

Info

Publication number
DE60324250D1
DE60324250D1 DE60324250T DE60324250T DE60324250D1 DE 60324250 D1 DE60324250 D1 DE 60324250D1 DE 60324250 T DE60324250 T DE 60324250T DE 60324250 T DE60324250 T DE 60324250T DE 60324250 D1 DE60324250 D1 DE 60324250D1
Authority
DE
Germany
Prior art keywords
integrin
inhibitors
beta
alpha
cell adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324250T
Other languages
German (de)
English (en)
Inventor
Ila Sircar
Marshall Morningstar
Masatoshi Kakushima
Hidefumi Kaji
Takayuki Kawaguchi
Toshiyuki Kume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60324250D1 publication Critical patent/DE60324250D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60324250T 2002-02-07 2003-02-06 Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion Expired - Fee Related DE60324250D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07
PCT/US2003/003449 WO2003066636A1 (en) 2002-02-07 2003-02-06 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

Publications (1)

Publication Number Publication Date
DE60324250D1 true DE60324250D1 (de) 2008-12-04

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324250T Expired - Fee Related DE60324250D1 (de) 2002-02-07 2003-02-06 Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion

Country Status (23)

Country Link
US (1) US7375128B2 (https=)
EP (1) EP1472257B1 (https=)
JP (1) JP2005517016A (https=)
KR (1) KR100625379B1 (https=)
CN (1) CN1301255C (https=)
AR (1) AR040068A1 (https=)
AT (1) ATE411995T1 (https=)
AU (1) AU2003210862B2 (https=)
BR (1) BR0307521A (https=)
CA (1) CA2474748A1 (https=)
CO (1) CO5601028A2 (https=)
DE (1) DE60324250D1 (https=)
EC (1) ECSP045222A (https=)
MX (1) MXPA04007643A (https=)
MY (1) MY137878A (https=)
NO (1) NO20043563L (https=)
NZ (1) NZ534208A (https=)
PE (1) PE20030899A1 (https=)
PL (1) PL372328A1 (https=)
RU (1) RU2315768C2 (https=)
TW (1) TW200303200A (https=)
WO (1) WO2003066636A1 (https=)
ZA (1) ZA200405647B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US20080262070A1 (en) * 2005-10-06 2008-10-23 Karl Baumann Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066B1 (en) * 2019-05-16 2025-08-20 Dispensing Dynamics International, Inc. Fragrance dispenser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
PT1307455E (pt) * 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2
IL152922A0 (en) * 2000-05-23 2003-06-24 Histatek Llc Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction

Also Published As

Publication number Publication date
ATE411995T1 (de) 2008-11-15
CN1301255C (zh) 2007-02-21
ECSP045222A (es) 2006-04-19
EP1472257B1 (en) 2008-10-22
KR20040091625A (ko) 2004-10-28
TW200303200A (en) 2003-09-01
EP1472257A1 (en) 2004-11-03
CA2474748A1 (en) 2003-08-14
MY137878A (en) 2009-03-31
PL372328A1 (en) 2005-07-11
KR100625379B1 (ko) 2006-09-20
US7375128B2 (en) 2008-05-20
PE20030899A1 (es) 2003-10-25
WO2003066636A1 (en) 2003-08-14
US20050171174A1 (en) 2005-08-04
RU2004123219A (ru) 2006-02-10
JP2005517016A (ja) 2005-06-09
AU2003210862B2 (en) 2006-10-26
AU2003210862A1 (en) 2003-09-02
BR0307521A (pt) 2004-12-28
RU2315768C2 (ru) 2008-01-27
NZ534208A (en) 2005-12-23
NO20043563L (no) 2004-11-01
ZA200405647B (en) 2005-07-15
MXPA04007643A (es) 2005-06-08
AR040068A1 (es) 2005-03-16
CO5601028A2 (es) 2006-01-31
CN1628116A (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
DK1501508T3 (da) Inhibitorer af histondeatylase
DK1505963T3 (da) Hepatitis C-inhibitorer
DE60109943D1 (de) Inhibitoren der durch alpha 4 vermittelten zelladhäsion
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
EP1499336A4 (en) PROTEASE INHIBITORS
NO20034955D0 (no) Korrosjonsinhibitor
DE60324418D1 (de) Nicht-nukleosidische inhibitoren der reversen transkriptase
DE60324250D1 (de) Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion
ATA92002A (de) Oberflächenschutz für lackierte flächen
AU2003292720A8 (en) Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same
FI20020317A7 (fi) Uudet tärkkelyspohjaiset liimat
DE60316425D1 (de) NF-kappaB-INHIBITOREN
DE60319277D1 (de) Beschichtungszusammensetzung
EP1552918A4 (en) GLOSS FOIL
NO20043610L (no) Fenylpyrimidinaminer som IgE inhibitorer
DE60305870D1 (de) Kathodische elektro-überzugsmittel
FR2843451B1 (fr) Fronde du type lance-pierres
DE60307471D1 (de) Hemmung
ITBO20020759A1 (it) Procedimento per lo stoccaggio di informazione ad
DE60326035D1 (de) Dipyridodiazepinone als inhibitoren der reversen transkriptase
ITMI20020468A0 (it) Dispositivo per la realizzazione di tetti
DK1529034T3 (da) Benzoylpyrazoloner substitueret med 3-aminocarbonyl
DE60225856D1 (de) Substraten
UA6680S (uk) Комплект етикеток
UA6801S (uk) Комплект етикеток

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee